Having demonstrated islet transdifferentiation in two distinct pancreatitis models, we reasoned that a factor common to pancreatitis in general must be having an important role. One feature common to ...
STRASBOURG, France, MONTREAL, BOSTON, March 20, 2025 /PRNewswire/ -- Domain Therapeutics ("Domain" or "the Company"), the GPCR experts harnessing deep receptor biology to develop breakthrough ...
Start of Phase 1 ascending dose studies in recurrent or metastatic solid tumors with DT-9045 is expected by mid-2025 DT-9045 builds upon the Company’s growing pipeline which includes the ...
Domain Therapeutics SA has disclosed proteinase-activated receptor 2 (PAR2; F2RL1) antagonists reported to be useful for the treatment of allergy, autoimmune and metabolic diseases, cardiovascular ...
Parmedics Inc. has described proteinase-activated PAR2 receptor antagonists reported to be useful for the treatment of asthma, cancer, osteoarthritis, migraine, chronic pain, inflammatory and vascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback